Protalix BioTherapeutics (PLX) EBT Margin (2010 - 2026)
Protalix BioTherapeutics' (PLX) quarterly EBT Margin came in at 62.64% in Q1 2026, up 9954.0% year-on-year from N/an in Q1 2025, and up 252.5% quarter-over-quarter from 41.08% in Q4 2025.
Protalix BioTherapeutics (PLX) EBT Margin (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' EBT Margin history runs 17 years deep, the most recent figure standing at 62.64% for Q1 2026.
- On a quarterly basis, EBT Margin rose 9954.0% year-over-year to 62.64% in Q1 2026; TTM through Mar 2026 was 26.57%, a 1033.0% increase from a year earlier, with the FY2025 full-year figure at 8.68%, down 2498.0% from the prior year.
- EBT Margin advanced to 62.64% in Q1 2026 per PLX's latest filing, from 41.08% in the prior quarter.
- Across five years, EBT Margin topped out at 65.12% in Q4 2024 and bottomed at 210.31% in Q4 2023.
- The 5-year median for EBT Margin is 16.86% (2024), against an average of 23.19%.
- Across the five-year window, EBT Margin slumped 17306 bps in 2023 and jumped 27543 bps in 2024, its largest moves.
- Year by year, EBT Margin stood at 37.25% in 2022, then slumped by 465 bps to 210.31% in 2023, then surged by 131 bps to 65.12% in 2024, then tumbled by 163 bps to 41.08% in 2025, then jumped by 252 bps to 62.64% in 2026.
- Per Business Quant, the three latest PLX EBT Margin figures stand at 62.64% (Q1 2026), 41.08% (Q4 2025), and 12.54% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Protalix BioTherapeutics | 190.95 Mn | 180.16 Mn | 29.62 Mn | 62.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62.64% |
| Dec 31, 2025 | -41.08% |
| Sep 30, 2025 | 12.54% |
| Jun 30, 2025 | 4.22% |
| Mar 31, 2025 | -36.90% |
| Dec 31, 2024 | 65.12% |
| Sep 30, 2024 | 21.40% |
| Jun 30, 2024 | -16.86% |
| Mar 31, 2024 | -126.28% |
| Dec 31, 2023 | -210.31% |
| Sep 30, 2023 | -16.62% |
| Jun 30, 2023 | 56.01% |
| Mar 31, 2023 | -30.62% |
| Dec 31, 2022 | -37.25% |
| Sep 30, 2022 | -25.15% |
| Jun 30, 2022 | -60.94% |
| Mar 31, 2022 | -14.21% |
| Dec 31, 2021 | -68.17% |
| Sep 30, 2021 | -35.63% |
| Jun 30, 2021 | -176.89% |